EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparable Outcomes of Differentiated Thyroid Cancer in Immunocompromised Versus Immunocompetent Patients

Amit Ritter iD, Alana Eagan, Helena Levyn, R Michael Tuttle, Snehal Patel, Ian Ganly iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf550 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Amit Ritter und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Immunocompromised Host, Neoplasm Recurrence, Local, Immunocompetence. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Differentiated thyroid cancer (DTC) is generally a highly treatable malignancy with low mortality and a favorable prognosis. However, the impact of immunodeficiency on DTC outcomes remains poorly understood, with research largely limited to organ transplant recipients. This study aimed to address this gap by comparing the clinical characteristics and outcomes of DTC in immunocompromised patients with a propensity-matched cohort of immunocompetent individuals.

Methods

The study compared adult patients with DTC and preexisting immunodeficiencies treated at Memorial Sloan-Kettering Cancer Center between 1987 and 2020 to a propensity-matched control group of immunocompetent patients, with a 5:1 comparison ratio. Data on demographics, disease characteristics, and outcomes were analyzed.

Results

Among 8534 DTC patients, 130 (1.5%) were immunocompromised. After propensity score matching, 650 immunocompetent patients were included for comparison. Recurrence-free survival did not differ significantly between groups (P = .94), with recurrence rates remaining below 10% in both cohorts over 180 months. At 10 years, disease-specific survival was also similar (P = .34), with rates of 100% for immunocompromised and 98% for immunocompetent patients.

Conclusion

DTC has a comparable prognosis in immunocompetent and immunocompromised patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsImmunocompromised HostNeoplasm Recurrence, LocalImmunocompetenceHumansMaleFemaleMiddle AgedAdultPrognosisAgedRetrospective StudiesPropensity ScoreFollow-Up StudiesSurvival RateDisease-Free SurvivalThyroidectomy

Stichwörter der Autor:innen

carcinomafollicularimmunocompromised hostimmunosuppressionpapillarythyroid neoplasms

Autor:innen und Institutionen

  • Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

ORCID-Profile: Amit Ritter, Ian Ganly

Zitieren

APA

Ritter, A., Eagan, A., Levyn, H., Tuttle, R. M., Patel, S., & Ganly, I. (2025). Comparable Outcomes of Differentiated Thyroid Cancer in Immunocompromised Versus Immunocompetent Patients. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf550

Vancouver

Ritter A, Eagan A, Levyn H, Tuttle RM, Patel S, Ganly I. Comparable Outcomes of Differentiated Thyroid Cancer in Immunocompromised Versus Immunocompetent Patients. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf550

BibTeX
@article{Ritter2025,
  author = {Ritter, Amit and Eagan, Alana and Levyn, Helena and Tuttle, R Michael and Patel, Snehal and Ganly, Ian},
  title = {Comparable Outcomes of Differentiated Thyroid Cancer in Immunocompromised Versus Immunocompetent Patients},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf550}
}
Kostenlos starten →